Table 2. Summary of commercially available, first-generation, multigene prognosticators in breast cancer.
| Endopredict | MammaPrint | MapQuant DX | Oncotype DX | PAM50 | Theros | |
|---|---|---|---|---|---|---|
| Number of Genes assessed | 8 | 70 | 97 | 21 | 50 | 2 |
| Types of tumour material | Fresh-frozen | FFPE | Fresh-frozen | FFPE | FFPE | FFPE |
| Technique | qRT-PCR | DNA microarrays | DNA microarrays | qRT-PCR | nCounter | qRT-PCR |
| BC subtype indication | ER+/HER2-BC treated with adjuvant ET |
Stage I or II BC, LN-, T ≤ 5 cm | ER+ Grade 2 BC, treated with adjuvant ET |
ER+ BC treated with adjuvant ET and/or CT | ER+ BC treated with adjuvant ET | ER+ BC treated with adjuvant ET |
| Prospective clinical evidence | No | Yes (MINDACT) | No | Yes (TAILORx) |
No | No |
| Regulatory approval | No | Yes (FDA) |
No | No | No | No |
| Company | Sividon Diagnostics | Agendia | Ipsogen | Genomic Health | Nanostring Technologies |
bioTheranostics |
Abbreviations: BC: breast cancer, CT: chemotherapy, ER: oestrogen receptor, ET: endocrine therapy, FDA: food and drug administration, HER2: human epidermal growth factor receptor 2, LN: lymph node, MINDACT: microarray in node-negative and 1–3 positive lymph node disease may avoid chemotherapy, qRT-PCR: q-reverse transcription polymerase chain reaction, TAILORx: trial assigning individualised options for treatment (Rx)